Sonia L. Betancourt Cuellar , Marcelo F. Benveniste , Diana Palacio , Afaf Atiyah , Wayne L. Hofstetter , Jeremy J. Erasmus
{"title":"18F-FDG-PET/CT对局部晚期印戒细胞食管腺癌分期有用吗?","authors":"Sonia L. Betancourt Cuellar , Marcelo F. Benveniste , Diana Palacio , Afaf Atiyah , Wayne L. Hofstetter , Jeremy J. Erasmus","doi":"10.1016/j.clinimag.2025.110545","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Signet-ring cell esophageal carcinoma (SRCEC) is a subtype of adenocarcinoma in which >10 %–50 % of cells have intracellular mucin. There is limited information regarding PET/CT in staging SRCEC. The purpose of this study is to evaluate the usefulness of PET/CT in staging patients with locally advanced SRCEC.</div></div><div><h3>Methods</h3><div>91 patients with biopsy-proven SRCEC and pretreatment FDG-PET/CT were included. SUVmax of the primary tumor, and size and SUVmax of regional lymph nodes were evaluated. In patients who had presurgical FDG-PET/CT after neoadjuvant therapy, response of the primary tumor and nodal metastases were assessed.</div></div><div><h3>Results</h3><div>Primary tumor was avid in 80/91 (88 %) (SUVmax range 3.8–28). Stage of 11 tumors without FDG uptake was T1N0–1 (<em>n</em> = 3), T2N0 (<em>n</em> = 1) and T3N0–2 (<em>n</em> = 7). 68 (75 %) patients had non-FDG avid nodes. Biopsy in 32/68 patients with non-FDG avid nodes was positive in 12 (38 %). 23 had FDG avid nodes, 14 were biopsied and 3 were positive for metastases.</div><div>After chemoradiation, 73 (86 %) had persistent FDG uptake in the primary tumor (SUVmax range 3.5–17.9) and 68 (93 %) had residual viable malignancy. 8/11 patients with resolution of FDG uptake in the primary tumor had persistent malignancy.</div><div>Regarding nodal metastases, 41/84 (49 %) had residual nodal disease in surgical specimens and only 4 (10 %) had nodes that were FDG avid.</div></div><div><h3>Conclusion</h3><div>PET/CT is useful in detecting the primary tumor in patients with SRCEC during the initial staging and after neoadjuvant therapy. The utility of PE/CT in detecting locoregional nodal disease prior to and after chemoradiation is limited.</div></div>","PeriodicalId":50680,"journal":{"name":"Clinical Imaging","volume":"125 ","pages":"Article 110545"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is 18F-FDG-PET/CT useful in staging of locally advanced signet-ring cell esophageal adenocarcinoma?\",\"authors\":\"Sonia L. Betancourt Cuellar , Marcelo F. Benveniste , Diana Palacio , Afaf Atiyah , Wayne L. Hofstetter , Jeremy J. Erasmus\",\"doi\":\"10.1016/j.clinimag.2025.110545\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Signet-ring cell esophageal carcinoma (SRCEC) is a subtype of adenocarcinoma in which >10 %–50 % of cells have intracellular mucin. There is limited information regarding PET/CT in staging SRCEC. The purpose of this study is to evaluate the usefulness of PET/CT in staging patients with locally advanced SRCEC.</div></div><div><h3>Methods</h3><div>91 patients with biopsy-proven SRCEC and pretreatment FDG-PET/CT were included. SUVmax of the primary tumor, and size and SUVmax of regional lymph nodes were evaluated. In patients who had presurgical FDG-PET/CT after neoadjuvant therapy, response of the primary tumor and nodal metastases were assessed.</div></div><div><h3>Results</h3><div>Primary tumor was avid in 80/91 (88 %) (SUVmax range 3.8–28). Stage of 11 tumors without FDG uptake was T1N0–1 (<em>n</em> = 3), T2N0 (<em>n</em> = 1) and T3N0–2 (<em>n</em> = 7). 68 (75 %) patients had non-FDG avid nodes. Biopsy in 32/68 patients with non-FDG avid nodes was positive in 12 (38 %). 23 had FDG avid nodes, 14 were biopsied and 3 were positive for metastases.</div><div>After chemoradiation, 73 (86 %) had persistent FDG uptake in the primary tumor (SUVmax range 3.5–17.9) and 68 (93 %) had residual viable malignancy. 8/11 patients with resolution of FDG uptake in the primary tumor had persistent malignancy.</div><div>Regarding nodal metastases, 41/84 (49 %) had residual nodal disease in surgical specimens and only 4 (10 %) had nodes that were FDG avid.</div></div><div><h3>Conclusion</h3><div>PET/CT is useful in detecting the primary tumor in patients with SRCEC during the initial staging and after neoadjuvant therapy. The utility of PE/CT in detecting locoregional nodal disease prior to and after chemoradiation is limited.</div></div>\",\"PeriodicalId\":50680,\"journal\":{\"name\":\"Clinical Imaging\",\"volume\":\"125 \",\"pages\":\"Article 110545\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0899707125001457\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Imaging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0899707125001457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Is 18F-FDG-PET/CT useful in staging of locally advanced signet-ring cell esophageal adenocarcinoma?
Objective
Signet-ring cell esophageal carcinoma (SRCEC) is a subtype of adenocarcinoma in which >10 %–50 % of cells have intracellular mucin. There is limited information regarding PET/CT in staging SRCEC. The purpose of this study is to evaluate the usefulness of PET/CT in staging patients with locally advanced SRCEC.
Methods
91 patients with biopsy-proven SRCEC and pretreatment FDG-PET/CT were included. SUVmax of the primary tumor, and size and SUVmax of regional lymph nodes were evaluated. In patients who had presurgical FDG-PET/CT after neoadjuvant therapy, response of the primary tumor and nodal metastases were assessed.
Results
Primary tumor was avid in 80/91 (88 %) (SUVmax range 3.8–28). Stage of 11 tumors without FDG uptake was T1N0–1 (n = 3), T2N0 (n = 1) and T3N0–2 (n = 7). 68 (75 %) patients had non-FDG avid nodes. Biopsy in 32/68 patients with non-FDG avid nodes was positive in 12 (38 %). 23 had FDG avid nodes, 14 were biopsied and 3 were positive for metastases.
After chemoradiation, 73 (86 %) had persistent FDG uptake in the primary tumor (SUVmax range 3.5–17.9) and 68 (93 %) had residual viable malignancy. 8/11 patients with resolution of FDG uptake in the primary tumor had persistent malignancy.
Regarding nodal metastases, 41/84 (49 %) had residual nodal disease in surgical specimens and only 4 (10 %) had nodes that were FDG avid.
Conclusion
PET/CT is useful in detecting the primary tumor in patients with SRCEC during the initial staging and after neoadjuvant therapy. The utility of PE/CT in detecting locoregional nodal disease prior to and after chemoradiation is limited.
期刊介绍:
The mission of Clinical Imaging is to publish, in a timely manner, the very best radiology research from the United States and around the world with special attention to the impact of medical imaging on patient care. The journal''s publications cover all imaging modalities, radiology issues related to patients, policy and practice improvements, and clinically-oriented imaging physics and informatics. The journal is a valuable resource for practicing radiologists, radiologists-in-training and other clinicians with an interest in imaging. Papers are carefully peer-reviewed and selected by our experienced subject editors who are leading experts spanning the range of imaging sub-specialties, which include:
-Body Imaging-
Breast Imaging-
Cardiothoracic Imaging-
Imaging Physics and Informatics-
Molecular Imaging and Nuclear Medicine-
Musculoskeletal and Emergency Imaging-
Neuroradiology-
Practice, Policy & Education-
Pediatric Imaging-
Vascular and Interventional Radiology